Merck & Co to buy Afferent for up to $1.25 billion
Merck & Co is buying clinical-stage biotech Afferent Pharmaceuticals in a deal worth up to $1.25 billion.
Read More
Tag: chronic cough
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
